Mipsagargin (G-202), a new prodrug developed by GenSpera, has a unique mechanism of action that allows it to kill cancer cells without damaging surrounding tissues. Derived from thapsigargin, the powerful toxin present in the Thapsia garganica plant, mipsagargin can combat any tumor with PSMA enzyme expression. This prodrug might be especially effective against both hepatocellular carcinoma and glioblastoma, as cancers of this type exhibit significant levels of PSMA.
G-202 is formed by attaching GenSpera’s patented peptide to the chemically-derived thapsigargin (12ADT) molecule. This peptide renders the thapsigargin inactive, allowing the toxin to travel through the body without affecting healthy tissue. The peptide can only be removed by bonding with a PSMA enzyme on a cancerous cell, which then allows the 12ADT molecule to enter the cell and destroy it.